Skip to content

Clinical Study on Oral Nemonoxacin Malate Capsules

Phase I Clinical Study on Oral Nemonoxacin Malate Capsules

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01395108
Enrollment
76
Registered
2011-07-15
Start date
2008-01-31
Completion date
2008-08-31
Last updated
2011-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Brief summary

The purpose of this study is to evaluate the safety and tolerability of nemonoxacin in healthy Chinese volunteers.

Detailed description

Single dose study: evaluate safety and tolerability of oral nemonoxacin 125 mg, 250mg, 500mg, 750mg, and 1000mg. Multiple dose study: evaluate PK profile of oral doses of 500mg or 750mg nemo after consecutive 10 days.

Interventions

oral once daily

Sponsors

TaiGen Biotechnology Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy males and females, aged between 18 and 45 during screening * Male volunteers who are capable of taking double-barrier contraception measures during the test (spermicide gel plus condom, for instance) until the end of the clinical study and do not cause their spouses to conceive within three months after the last administration of the medication; if the subjects are females, they shall not become pregnant during the test and within three months after the study * No use of tobacco or nicotine product within 3 months prior to this study * BMI 19-25 * Willing to abstain from coffee and any caffeine drink during the study * Voluntarily sign the informed consent

Exclusion criteria

* History of diabetes, or cardiovascular, hepatic or renal disease * Active digestive disease (e.g. diarrhea) * Central nervous disease or psychiatric disorders * Had surgery or trauma within 6 months prior to this study * Alcohol or drug abuse * HIV, HBV or HCV positive * Used any prescribed drug (including traditional chinese medicine) within 14 days prior to the study * Donated 400ml of blood or plasma within 3 months prior to this study * Have an abnormal laboratory examination value that exceeds the normal range by 10% * Drug allergies * Have cardiac disorders or have a family history of cardiac disorders * Have abnormal 12-lead ECG during screening * Pregnant or lactating * Participated in any study within 3 months prior to this study

Design outcomes

Primary

MeasureTime frame
Maximum tolerated single oral dose of nemonoxacin in healthy Chinese volunteers7 days
Pharmacokinetic profile of single oral dose of nemonoxacin in healthy Chinese volunteers7 days
Pharmacokinetic profile of repeated oral doses of nemonoxacin in healthy Chinese volunteers17 days

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026